175 related articles for article (PubMed ID: 37796613)
1. Risk Factors for Chronic Obstructive Pulmonary Disease Exacerbations among Individuals without a History of Recent Exacerbations: A COPDGene Analysis.
Ferrera MC; Lopez CL; Murray S; Jain RG; Labaki WW; Make BJ; Han MK
Ann Am Thorac Soc; 2024 Mar; 21(3):421-427. PubMed ID: 37796613
[No Abstract] [Full Text] [Related]
2. Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease.
Dransfield MT; Kunisaki KM; Strand MJ; Anzueto A; Bhatt SP; Bowler RP; Criner GJ; Curtis JL; Hanania NA; Nath H; Putcha N; Roark SE; Wan ES; Washko GR; Wells JM; Wendt CH; Make BJ;
Am J Respir Crit Care Med; 2017 Feb; 195(3):324-330. PubMed ID: 27556408
[TBL] [Abstract][Full Text] [Related]
3. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort.
Han MK; Quibrera PM; Carretta EE; Barr RG; Bleecker ER; Bowler RP; Cooper CB; Comellas A; Couper DJ; Curtis JL; Criner G; Dransfield MT; Hansel NN; Hoffman EA; Kanner RE; Krishnan JA; Martinez CH; Pirozzi CB; O'Neal WK; Rennard S; Tashkin DP; Wedzicha JA; Woodruff P; Paine R; Martinez FJ;
Lancet Respir Med; 2017 Aug; 5(8):619-626. PubMed ID: 28668356
[TBL] [Abstract][Full Text] [Related]
4. Predicting exacerbations in COPD in the Danish general population.
Marott JL; Ingebrigtsen TS; Çolak Y; Vestbo J; Nordestgaard BG; Lange P
Respir Med; 2024 Apr; 224():107557. PubMed ID: 38355020
[TBL] [Abstract][Full Text] [Related]
5. Therapy with proton-pump inhibitors for gastroesophageal reflux disease does not reduce the risk for severe exacerbations in COPD.
Baumeler L; Papakonstantinou E; Milenkovic B; Lacoma A; Louis R; Aerts JG; Welte T; Kostikas K; Blasi F; Boersma W; Torres A; Rohde GG; Boeck L; Rakic J; Scherr A; Tamm M; Stolz D
Respirology; 2016 Jul; 21(5):883-90. PubMed ID: 26970108
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers Predictive of Exacerbations in the SPIROMICS and COPDGene Cohorts.
Keene JD; Jacobson S; Kechris K; Kinney GL; Foreman MG; Doerschuk CM; Make BJ; Curtis JL; Rennard SI; Barr RG; Bleecker ER; Kanner RE; Kleerup EC; Hansel NN; Woodruff PG; Han MK; Paine R; Martinez FJ; Bowler RP; O'Neal WK;
Am J Respir Crit Care Med; 2017 Feb; 195(4):473-481. PubMed ID: 27579823
[TBL] [Abstract][Full Text] [Related]
7. Predicting severe chronic obstructive pulmonary disease exacerbations using quantitative CT: a retrospective model development and external validation study.
Chaudhary MFA; Hoffman EA; Guo J; Comellas AP; Newell JD; Nagpal P; Fortis S; Christensen GE; Gerard SE; Pan Y; Wang D; Abtin F; Barjaktarevic IZ; Barr RG; Bhatt SP; Bodduluri S; Cooper CB; Gravens-Mueller L; Han MK; Kazerooni EA; Martinez FJ; Menchaca MG; Ortega VE; Iii RP; Schroeder JD; Woodruff PG; Reinhardt JM
Lancet Digit Health; 2023 Feb; 5(2):e83-e92. PubMed ID: 36707189
[TBL] [Abstract][Full Text] [Related]
8. The phenotype of concurrent chronic bronchitis and frequent exacerbations in patients with severe COPD attending Swedish secondary care units.
Sundh J; Johansson G; Larsson K; Lindén A; Löfdahl CG; Sandström T; Janson C
Int J Chron Obstruct Pulmon Dis; 2015; 10():2327-34. PubMed ID: 26604732
[TBL] [Abstract][Full Text] [Related]
9. Association of gastroesophageal reflux disease risk with exacerbations of chronic obstructive pulmonary disease.
Liang B; Wang M; Yi Q; Feng Y
Dis Esophagus; 2013 Aug; 26(6):557-60. PubMed ID: 23301861
[TBL] [Abstract][Full Text] [Related]
10. Combined Forced Expiratory Volume in 1 Second and Forced Vital Capacity Bronchodilator Response, Exacerbations, and Mortality in Chronic Obstructive Pulmonary Disease.
Fortis S; Comellas A; Make BJ; Hersh CP; Bodduluri S; Georgopoulos D; Kim V; Criner GJ; Dransfield MT; Bhatt SP;
Ann Am Thorac Soc; 2019 Jul; 16(7):826-835. PubMed ID: 30908927
[No Abstract] [Full Text] [Related]
11. Impact of gastroesophageal reflux on longitudinal lung function and quantitative computed tomography in the COPDGene cohort.
Baldomero AK; Wendt CH; Petersen A; Gaeckle NT; Han MK; Kunisaki KM;
Respir Res; 2020 Aug; 21(1):203. PubMed ID: 32746820
[TBL] [Abstract][Full Text] [Related]
12. Persistent and Newly Developed Chronic Bronchitis Are Associated with Worse Outcomes in Chronic Obstructive Pulmonary Disease.
Kim V; Zhao H; Boriek AM; Anzueto A; Soler X; Bhatt SP; Rennard SI; Wise R; Comellas A; Ramsdell JW; Kinney GL; Han MK; Martinez CH; Yen A; Black-Shinn J; Porszasz J; Criner GJ; Hanania NA; Sharafkhaneh A; Crapo JD; Make BJ; Silverman EK; Curtis JL;
Ann Am Thorac Soc; 2016 Jul; 13(7):1016-25. PubMed ID: 27158740
[TBL] [Abstract][Full Text] [Related]
13. Immunostimulants versus placebo for preventing exacerbations in adults with chronic bronchitis or chronic obstructive pulmonary disease.
Fraser A; Poole P
Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013343. PubMed ID: 36373977
[TBL] [Abstract][Full Text] [Related]
14. Impact of comorbidities in COPD clinical control criteria. The CLAVE study.
Almagro P; Soler-Cataluña JJ; Huerta A; González-Segura D; Cosío BG;
BMC Pulm Med; 2024 Jan; 24(1):6. PubMed ID: 38166965
[TBL] [Abstract][Full Text] [Related]
15. GOLD 2011 disease severity classification in COPDGene: a prospective cohort study.
Han MK; Muellerova H; Curran-Everett D; Dransfield MT; Washko GR; Regan EA; Bowler RP; Beaty TH; Hokanson JE; Lynch DA; Jones PW; Anzueto A; Martinez FJ; Crapo JD; Silverman EK; Make BJ
Lancet Respir Med; 2013 Mar; 1(1):43-50. PubMed ID: 24321803
[TBL] [Abstract][Full Text] [Related]
16. A clinical prediction model for hospitalized COPD exacerbations based on "treatable traits".
Yii ACA; Loh CH; Tiew PY; Xu H; Taha AAM; Koh J; Tan J; Lapperre TS; Anzueto A; Tee AKH
Int J Chron Obstruct Pulmon Dis; 2019; 14():719-728. PubMed ID: 30988606
[TBL] [Abstract][Full Text] [Related]
17. Examining the Effects of Age on Health Outcomes of Chronic Obstructive Pulmonary Disease: Results From the Genetic Epidemiology of Chronic Obstructive Pulmonary Disease Study and Evaluation of Chronic Obstructive Pulmonary Disease Longitudinally to Identify Predictive Surrogate Endpoints Cohorts.
Parulekar AD; Martinez C; Tsai CL; Locantore N; Atik M; Yohannes AM; Kao CC; Al-Azzawi H; Mohsin A; Wise RA; Foreman MG; Demeo DL; Regan EA; Make BJ; Boriek AM; Wiener LE; Hanania NA
J Am Med Dir Assoc; 2017 Dec; 18(12):1063-1068. PubMed ID: 29169736
[TBL] [Abstract][Full Text] [Related]
18. Impact of Prolonged Exacerbation Recovery in Chronic Obstructive Pulmonary Disease.
Donaldson GC; Law M; Kowlessar B; Singh R; Brill SE; Allinson JP; Wedzicha JA
Am J Respir Crit Care Med; 2015 Oct; 192(8):943-50. PubMed ID: 26151174
[TBL] [Abstract][Full Text] [Related]
19. Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease.
van Geffen WH; Tan DJ; Walters JA; Walters EH
Cochrane Database Syst Rev; 2023 Dec; 12(12):CD011600. PubMed ID: 38054551
[TBL] [Abstract][Full Text] [Related]
20. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population.
Pasquale MK; Sun SX; Song F; Hartnett HJ; Stemkowski SA
Int J Chron Obstruct Pulmon Dis; 2012; 7():757-64. PubMed ID: 23152680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
